Citations

Clear

382 citation(s) found for "Shapiro, CL".

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Abida, Wassim , Campbell, David , Patnaik, Akash , Shapiro, Jeremy , Sautois, Brieuc , Vogelzang, Nicholas J. , Voog, Éric , Bryce, Alan H. , McDermott, Ray , Ricci, Francesco , Zhang, Jingsong , Piulats, Josep M. , Fizazi, Karim , Merseburger, Axel S. , Higano, Celestia S. , Krieger, Laurence E. , Ryan, Charles J. , Feng, Felix Y. , Simmons, Andrew D. , Loehr, Andrea , Despain, Darrin , Dowson, Melanie, Green, Foad, Watkins, Simon P. , Golsorkhi, Tony, Chowdhury, Simon, Simmons, Andrew D , Watkins, Simon P , Golsorkhi, Tony , Bryce, Alan H , Vogelzang, Nicholas J , McDermott, Ray , Patnaik, Akash , Rowe, Julie Haewon

Mayo Clinic

Clinical Cancer Research | February 21, 2020 | Volume: 26 | Issue: 11 | Pages: 2487-2496

10.1158/1078-0432.ccr-20-0394 | PMID 32086346 Get It

Abstract Purpose: Genomic alterations in DNA damage repair (DDR) genes other than BRCA may confer synthetic lethality with PARP inhibition in metastatic castration-resistant prostate cancer (mCRPC). To test this hypothesis, the phase II TRITON2 study of rucaparib included patients with mCRPC and deleterious non-BRCA DDR gene alterations. Patients and Methods: TRITON2 enrolled patients who had progressed on one or two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy for mCRPC. Key endpoints were investigator-assessed radiographic response per modified RECIST/PCWG3 and PSA response (≥50% decrease from baseline). Results: TRITON2 enrolled 78 patients with a non-BRCA DDR gene alteration [ATM (n = 49), CDK12 (n = 15), CHEK2 (n = 12), and other DDR genes (n = 14)]. Among patients evaluable for each endpoint, radiographic and PSA responses were observed in a limited number of patients with an alteration in ATM [2/19 (10.5%) and 2/49 (4.1%), respectively], CDK12 [0/10 (0%) and 1/15 (6.7%), respectively], or CHEK2 [1/9 (11.1%) and 2/12 (16.7%), respectively], including no radiographic or PSA responses in 11 patients with confirmed biallelic ATM loss or 11 patients with ATM germline mutations. Responses were observed in patients with alterations in the DDR genes PALB2, FANCA, BRIP1, and RAD51B. Conclusions: In this prospective, genomics-driven study of rucaparib in mCRPC, we found limited radiographic/PSA responses to PARP inhibition in men with alterations in ATM, CDK12, or CHEK2. However, patients with alterations in other DDR-associated genes (e.g., PALB2) may benefit from PARP inhibition. See related commentary by Sokolova et al., p. 2439
Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC).
Abida, Wassim , Campbell, David , Shapiro, Jeremy , McDermott, Raymond S., Ricci, Francesco , Zhang, Jingsong , Loehr, Andrea , Despain, Darrin , Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, Patnaik, Akash , Sautois, Brieuc , Vogelzang, Nicholas J. , Bryce, Alan H. , McDermott, Raymond S., Rowe, Julie Haewon

Mayo Clinic

Journal of Clinical Oncology | February 19, 2020 | Volume: 38 | Issue: 6_suppl | Pages: 178-178

10.1200/jco.2020.38.6_suppl.178 Get It

178 Background: The phase 2 TRITON2 study (NCT02952534) is evaluating the PARP inhibitor rucaparib in pts with mCRPC and a deleterious germline or somatic alteration in BRCA ( BRCA pts) or 1 of 13 other DNA damage repair (DDR) genes. Methods: Eligible pts had progressed on 1–2 lines of androgen receptor-directed therapy and 1 taxane-based chemotherapy. Deleterious DDR gene alterations were identified from central testing of plasma and/or tissue samples by Foundation Medicine or from local testing. Results: As of Jul 2, 2019 (visit cutoff), 98 BRCA pts had received rucaparib; median (range) duration of follow-up was 13.0 (4.1–25.8) mo. Confirmed objective response rate (ORR) in BRCA pts (with investigator-assessed measurable disease) and PSA response rates (in pts with and without measurable disease) are shown in the Table. A biallelic alteration was observed in 81.4% (35/43) of BRCA pts for whom zygosity could be determined, and pts with homozygous BRCA loss (20.4%; 20/98) demonstrated high ORR (66.7% [95% CI, 38.4-88.2]; 10/15) and PSA response rates (75.0% [95% CI, 50.9-91.3]; 15/20). The safety profile in BRCA pts was consistent with the overall TRITON2 pt population. Conclusions: Results from TRITON2 showed antitumor activity with rucaparib in pts with mCRPC and a deleterious BRCA alteration. Responses were observed in patients with germline or somatic alterations in BRCA1 or BRCA2. The activity of rucaparib in these and additional genomic subgroups (e.g., based on zygosity, plasma genomic testing, or co-occurring alterations) will be reported. Clinical trial information: NCT02952534. [Table: see text]
Adipose‐Derived Biogenic Nanoparticles for Suppression of Inflammation
Tian, Ming , Ticer, Taylor , Walker, Sierra A. , Pham, Anthony , Suh, Annie, Busatto, Sara , Davidovich, Irina, Al‐kharboosh, Rawan , Lewis‐Tuffin, Laura J. , Ji, Baoan , Quiñones‐Hinojosa, Alfredo , Rückert, Felix , Wolfram, Joy , Wang, Qikun, Walker, Sierra, Al-Kharboosh, Rawan, Lewis-Tuffin, Laura, Wolfram, Joy , Wang, Qikun , Talmon, Yeshayahu , Shapiro, Shane A.

Mayo Clinic

Small | February 18, 2020 | Volume: 16 | Issue: 10 | Pages: No page available

10.1002/smll.201904064 | PMID 32067382 Get It

Abstract Extracellular vesicles secreted from adipose‐derived mesenchymal stem cells (ADSCs) have therapeutic effects in inflammatory diseases. However, production of extracellular vesicles (EVs) from ADSCs is costly, inefficient, and time consuming. The anti‐inflammatory properties of adipose tissue‐derived EVs and other biogenic nanoparticles have not been explored. In this study, biogenic nanoparticles are obtained directly from lipoaspirate, an easily accessible and abundant source of biological material. Compared to ADSC‐EVs, lipoaspirate nanoparticles (Lipo‐NPs) take less time to process (hours compared to months) and cost less to produce (clinical‐grade cell culture facilities are not required). The physicochemical characteristics and anti‐inflammatory properties of Lipo‐NPs are evaluated and compared to those of patient‐matched ADSC‐EVs. Moreover, guanabenz loading in Lipo‐NPs is evaluated for enhanced anti‐inflammatory effects. Apolipoprotein E and glycerolipids are enriched in Lipo‐NPs compared to ADSC‐EVs. Additionally, the uptake of Lipo‐NPs in hepatocytes and macrophages is higher. Lipo‐NPs and ADSC‐EVs have comparable protective and anti‐inflammatory effects. Specifically, Lipo‐NPs reduce toll‐like receptor 4‐induced secretion of inflammatory cytokines in macrophages. Guanabenz‐loaded Lipo‐NPs further suppress inflammatory pathways, suggesting that this combination therapy can have promising applications for inflammatory diseases.
Signs of Increased Intrapericardial Pressure on Chest Computed Tomography
Rojas, Carlos, Padilla, Gary, Feldhaus, Jacob M., Rajan, Celin, Shapiro, Brian P. , Mergo, Patricia J. , Livingston, David H. , Bowman, Andrew W.

Mayo Clinic

Journal of Thoracic Imaging | February 7, 2020 | Volume: 35 | Issue: 3 | Pages: 143-152

10.1097/rti.0000000000000475 | PMID 32073542 Get It

We sought to describe incidental imaging features of increased intrapericardial pressure due to pericardial effusion on chest computed tomography (CT) and correlate them with cardiac CT, cardiac magnetic resonance imaging, and echocardiography. It is important for the radiologist to become familiar with imaging findings of increased intrapericardial pressure in the setting of pericardial effusion when identified on chest CT. Recognizing the imaging findings of increased intrapericardial pressure can better guide the care of these patients.
Glenohumeral Osteoarthritis: The Role for Orthobiologic Therapies
Rossi, Luciano Andrés , Piuzzi, Nicolás S. , Shapiro, Shane A. , Shapiro, Shane , Rossi, Luciano A

Mayo Clinic

JBJS Reviews | February 4, 2020 | Volume: 8 | Issue: 2 | Pages: e0075-e0075

10.2106/jbjs.rvw.19.00075 | PMID 32015271 Get It

» The glenohumeral (GH) joint ranks third on the list of the large joints that are most commonly affected by osteoarthritis, after the knee and the hip. » General nonsurgical modalities, including changes in daily activities, physical therapy, pharmacotherapy, and corticosteroid injections, constitute the mainstay of treatment. Most of these options, however, have shown moderate and short-term effectiveness. » Arthroplasty techniques have proven to be successful for elderly patients. Nevertheless, replacement options are not optimal for younger patients because their functional demands are higher and prostheses have a finite life span. » This has led to the search for new nonoperative treatment options to target this subgroup of patients. It has been suggested that orthobiologic therapies, including platelet-rich plasma (PRP) and cell therapies, present great promise and opportunity for the treatment of GH osteoarthritis. » Despite the promising results that have been shown by cell therapies and PRP for treating degenerative joint conditions, additional studies are needed to provide more definitive conclusions.
History and evolution of regional anesthesiology and acute pain medicine fellowship training
Shapiro, David , Hargett, Mary J. , Neal, Joseph M. , Mariano, Edward R. , Liguori, Gregory A., Shapiro, David Michael , Mariano, Edward R , Kopp, Sandra L.

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 30, 2020 | Volume: 45 | Issue: 4 | Pages: 311-314

10.1136/rapm-2019-100915 | PMID 32001624 Get It

Introduction In 2016, individual training programs in regional anesthesiology and acute pain medicine (RA/APM) became eligible for accreditation by the Accreditation Council for Graduate Medical Education (ACGME), thereby culminating a process that began 15 years earlier. Herein, we review the origins of regional anesthesia training in the USA, the events leading up to accreditation and the current state of the fellowship. Methods We reviewed pertinent literature on the historical aspects of RA/APM in the USA, related subspecialty training and the formation and current state of RA/APM fellowship training programs. Additionally, a survey was distributed to the directors of the 74 RA/APM fellowships that existed as of 1 January 2017 to gather up-to-date, program-specific information. Results The survey yielded a 76% response rate. Mayo Clinic Rochester and Virginia Mason Medical Center likely had the first structured RA/APM fellowships with formalized curriculums and stated objectives, both starting in 1982. Most programs (86%), including ACGME and non-ACGME fellowships, came into existence after the year 2000. Six responding programs have or previously had RA/APM comingled with another subspecialty. Eight current programs originally offered unofficial or part-time fellowships in RA/APM, with fellows also practicing as attending physicians. Discussion The history of RA/APM training in the USA is a tortuous one. It began with short ‘apprenticeships’ under the tutelage of the early proponents of regional anesthesia and continues today with 84 official RA/APM programs and a robust fellowship directors’ group. RA/APM programs teach skills essential to the practice and improvement of anesthesiology as a specialty.
Chromatin-Modifying Enzymes in T Cell Development
Shapiro, Michael J. , Shapiro, Virginia Smith , Shapiro, Michael J.

Mayo Clinic

Annual Review of Immunology | January 28, 2020 | Volume: 38 | Issue: 1 | Pages: 397-419

10.1146/annurev-immunol-092719-082622 | PMID 31990620 Get It

T cell development involves stepwise progression through defined stages that give rise to multiple T cell subtypes, and this is accompanied by the establishment of stage-specific gene expression. Changes in chromatin accessibility and chromatin modifications accompany changes in gene expression during T cell development. Chromatin-modifying enzymes that add or reverse covalent modifications to DNA and histones have a critical role in the dynamic regulation of gene expression throughout T cell development. As each chromatin-modifying enzyme has multiple family members that are typically all coexpressed during T cell development, their function is sometimes revealed only when two related enzymes are concurrently deleted. This work has also revealed that the biological effects of these enzymes often involve regulation of a limited set of targets. The growing diversity in the types and sites of modification, as well as the potential for a single enzyme to catalyze multiple modifications, is also highlighted.
Cash-Based Stem-Cell Clinics
Taliaferro, John , Shapiro, Shane A. , Montero, Daniel , Shi, Glenn G. , Wilke, Benjamin K. , Montero, Daniel P, Shapiro, Shane , Wilke, B K , Shi, Glenn G

Mayo Clinic

JBJS Case Connector | December 9, 2019 | Volume: 9 | Issue: 4 | Pages: e0363-e0363

10.2106/jbjs.cc.19.00363 | PMID 31815806 Get It

Update This article was updated on January 14, 2020, because of a previous error. On page 1, in the Abstract and the section entitled “Case Reports,” the word that had read “Genentech“ now reads “Genetech.” An erratum has been published: JBJS Case Connect. 2020 Feb 5;10(1):e0363ER. Case: The use of biologics is rapidly expanding. Over the past decade, there has been a significant increase in the number of cash-based “stem cell”/regenerative medicine clinics in the United States. These clinics provide cash-based services touting stem cell injections to cure a myriad of conditions. Largely, these clinics are unregulated and using injections in a non–Food and Drug Administration–approved manner. We report on 2 patients who presented with symptoms suggestive of septic arthritis following stem cell injections by cash-based local stem cell clinics. Case 1 involved a patient who developed septic arthritis following an injection of umbilical cord blood–derived cellular products (Genetech) and required an antibiotic spacer followed by a total hip arthroplasty. Case 2 involved a patient who developed a likely immune-mediated reaction following an injection of morselized human placental allograft tissue by a local chiropractic office at a cost of approximately $8,000. Conclusions: We present these cases to bring increased awareness to the issue and call for increased regulation of this practice.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dobelbower, M.C., Gettinger, Scott , Govindan, Ramaswamy , Gubens, Matthew A. , Hennon, Mark, Horn, Leora , Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Loo, Billy W. , Martins, Renato , Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Stevenson, James, Swanson, Scott J. , Tauer, Kurt W., Yang, Stephen C. , Gregory, Kristina M., OCN, Hughes, Miranda, Schild, Steven E. , Loo, Billy W , Govindan, Ramaswamy , Aggarwal, Charu , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Reckamp, Karen L. , OCN, Hughes, Miranda

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 5, 2019 | Volume: 17 | Issue: 12 | Pages: 1464-1472

10.6004/jnccn.2019.0059 | PMID 31805526 Get It

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”